News and Views

Clinical trials: Treatment of HCV-infected patients with advanced kidney disease

Antiviral treatment options for HCV-infected patients with advanced kidney disease are limited because few clinical trials have tested the efficacy of antiviral drugs in this population. Now, a phase III trial of two pan-genotypic drugs demonstrates excellent viral clearance with minimal adverse events in HCV-infected patients with advanced kidney disease.

  • Subscribe to Nature Reviews Nephrology for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , & Hepatitis C virus infection in chronic kidney disease. J. Am. Soc. Nephrol. 27, 2238–2246 (2016).

  2. 2.

    , & Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J. Viral Hepat. 19, 601–617 (2012).

  3. 3.

    et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61, 1495–1502 (2015).

  4. 4.

    et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin. J. Am. Soc. Nephrol. 12, 287–297 (2017).

  5. 5.

    et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N. Engl. J. Med. 377, 1448–1455 (2017).

  6. 6.

    et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 36, 807–816 (2016).

  7. 7.

    et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 1537–1545 (2015).

  8. 8.

    et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150, 1590–1598 (2016).

  9. 9.

    et al. in AASLD The Liver Meeting abstract 935 (Boston, 2016).

  10. 10.

    et al. in AASLD The Liver Meeting abstract 1946 (Boston, 2016).

Download references

Author information

Affiliations

  1. Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, Florida 33136, USA; and at The Miami Veterans Administration Medical Center, 1201 NW 16th Street, Miami, Florida 33125, USA.

    • Marco Ladino
  2. Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, Florida 33136, USA.

    • David Roth

Authors

  1. Search for Marco Ladino in:

  2. Search for David Roth in:

Competing interests

M.L. declares no competing interests. D.R. is a consultant and is on the Scientific Advisory Boards for Merck & Co. and AbbVie.

Corresponding author

Correspondence to David Roth.